Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML

Tao Dao, Guangyan Xiong, Sung Soo Mun, Jeremy Meyerberg, Tatyana Korontsvit, Jingyi Xiang, Ziyou Cui, Aaron Y. Chang, Casey Jarvis, Winson Cai, Hanzhi Luo, Aspen Pierson, Anthony Daniyan, Sarah Yoo, Sumiko Takao, Michael Kharas, Alex Kentsis, Cheng Liu, David A. Scheinberg

Blood (2024) 143 (6): 507–521.

https://doi.org/10.1182/blood.2023021054

Published: 2024

Includes: Supplemental data

Journal Articles

Potent and Target Specific Cytotoxicity of PRAME TCR Mimic CAR T Cells in KMT2A-Rearranged AML Patient-Derived Xenograft Model

Danielle C Kirkey, Leila Robinson, Tiffany Hylkema, Anisha Loeb, Rhonda E Ries, Cyd McKay, Christina Root, Laura Pardo, Keith R. Loeb, Quy Le, David A. Scheinberg, Soheil Meshinchi

Blood (2023) 142 (Supplement 1): 4821.

https://doi.org/10.1182/blood-2023-188391

Published: 2023

Journal Articles

Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blocker

Megan M. Dacek, Keifer G. Kurtz, Patrick Wallisch, Stephanie A. Pierre, Shireen Khayat, Christopher M. Bourne, Thomas J. Gardner, Kristen C. Vogt, Nica Aquino, Anas Younes, David A. Scheinberg

Blood (2023) 141 (16): 2003–2015.

https://doi.org/10.1182/blood.2022016101

Published: 2023

Includes: Supplemental data

Journal Articles

A TCR mimic CAR T cell specific for NDC80 is broadly reactive with solid tumors and hematologic malignancies

Martin G. Klatt, Tao Dao, Zhiyuan Yang, Jianying Liu, Sung Soo Mun, Megan M. Dacek, Hanzhi Luo, Thomas J. Gardner, Christopher Bourne, Leila Peraro, Zita E. H. Aretz, Tanya Korontsvit, Michael Lau, Michael G. Kharas, Cheng Liu, David A. Scheinberg

Blood (2022) 140 (8): 861–874.

https://doi.org/10.1182/blood.2021012882

Published: 2022

Includes: Supplemental data

Journal Articles

Targeting PRAME with TCR-Mimic CAR T Cells in AML

Anisha M Loeb, Sommer Castro, Cynthia Nourigat-Mckay, LaKeisha Perkins, Laura Pardo, Amanda R. Leonti, Thao T. Tang, Lindsey F Call, Tiffany A. Hylkema, David A. Scheinberg, Soheil Meshinchi, Quy Le

Blood (2021) 138 (Supplement 1): 733.

https://doi.org/10.1182/blood-2021-148677

Published: 2021

Journal Articles

A TCR Mimic Antibody-Directed CAR T Cell Specific for Intracellular NDC80 Is Broadly Cancer Reactive and Displays High Activity Against Hematological Malignancies

Martin G. Klatt, MD, Zhiyuan Yang, PhD, Jianying Liu, PhD, Tatyana Korontsvit, MD, Sung Soo Mun, Leila Peraro, PhD, Thomas J. Gardner, PhD, Christopher Bourne, Megan M. Dacek, Tao Dao, MD PhD, Cheng Liu, PhD, David A. Scheinberg, MD PhD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-140179

Published: 2020

Journal Articles

The Tumor Associated Antigen PRAME Exhibits Dualistic Functions That Are Targetable in Diffuse Large B-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-141168

Published: 2020

Journal Articles

Epigenetic Drug Treatment Induces Presentation of New Class of Non-Exonic, Cryptic Neoantigens in Acute Myeloid Leukemia Cells

Martin G. Klatt, MD, Sung S. Mun, Nicholas D. Socci, PhD, Tatyana Korontsvit, MD, Tao Dao, MD PhD, David A. Scheinberg, MD PhD

Blood (2018) 132 (Supplement 1): 2717.

https://doi.org/10.1182/blood-2018-99-113691

Published: 2018

Journal Articles

A Phase 2 Study of Actinium-225 ( 225 Ac)-Lintuzumab in Older Patients with Previously Untreated Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy

Laura E. Finn, MD, Moshe Levy, MD, Johnnie J. Orozco, MD PhD, Jae H. Park, MD, Ehab Atallah, MD, Michael Craig, MD, Alexander E. Perl, MD, David A. Scheinberg, MDPhD, Dragan Cicic, MD, Gregory Richard Bergonio, MSc, BSN, Mark S. Berger, MD, Joseph G. Jurcic, MD

Blood (2017) 130 (Supplement 1): 2638.

https://doi.org/10.1182/blood.V130.Suppl_1.2638.2638

Published: 2017

Journal Articles

Identification of Cross-Reactive Targets of TCR-Based Therapeutic Agents within the Human Proteome

Ron S Gejman, BA, Tao Dao, MDPhD, David A. Scheinberg, MDPhD

Blood (2017) 130 (Supplement 1): 3188.

https://doi.org/10.1182/blood.V130.Suppl_1.3188.3188

Published: 2017

Journal Articles

Immune reconstitution and remission in CML

David A. Scheinberg

Blood (2017) 129 (9): 1064–1065.

https://doi.org/10.1182/blood-2017-01-761569

Published: 2017

Journal Articles

Dual Inhibition of Histone Deacetylases and Phosphoinositide 3-Kinase Enhances Therapeutic Activity Against B Cell Lymphoma

Patrizia Mondello, MD MSc, Enrico Derenzini, MD, Zahra Asgari, John Philip, Elliot J Brea, PhD, Venkatraman E Seshan, PhD, Ronald Hendrickson, PhD, Elisa de Stanchina, PhD, David A Scheinberg, MD PhD, Anas Younes, MD

Blood (2016) 128 (22): 293.

https://doi.org/10.1182/blood.V128.22.293.293

Published: 2016

Journal Articles

CD47 Blockade Enhances Therapeutic Activity of TCR Mimic Antibodies to Ultra-Low Density Cancer Epitopes through Cytokine Feed Forward Mechanisms

Melissa D Mathias, MD, Jonathan T Sockolosky, PhD, Aaron Yu-Yuan Chang, BS, Cheng Liu, PhD, K. Christopher Garcia, PhD, David A. Scheinberg, MD PhD

Blood (2016) 128 (22): 4048.

https://doi.org/10.1182/blood.V128.22.4048.4048

Published: 2016

Journal Articles

Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 ( 225 Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML)

Joseph G. Jurcic, MD, Moshe Yair Levy, MD, Jae H. Park, MD, Farhad Ravandi, MD, Alexander E. Perl, MD, John M. Pagel, MD PhD, B. Douglas Smith, MD, Elihu H. Estey, MD, Hagop Kantarjian, MD, Dragan Cicic, MD, David A. Scheinberg, MD PhD

Blood (2016) 128 (22): 4050.

https://doi.org/10.1182/blood.V128.22.4050.4050

Published: 2016

Journal Articles

A Therapeutic TCR Mimic Monoclonal Antibody for Intracellular PRAME Protein in Leukemias

Aaron Chang, Tao Dao, PhD, Andrew Scott, Leonid Dubrovsky, MD, Cheng Liu, PhD, David A. Scheinberg, MD PhD

Blood (2015) 126 (23): 2527.

https://doi.org/10.1182/blood.V126.23.2527.2527

Published: 2015

Journal Articles

Phase I Trial of Targeted Alpha-Particle Immunotherapy with Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33) and Low-Dose Cytarabine (LDAC) in Older Patients with Untreated Acute Myeloid Leukemia (AML)

Joseph G. Jurcic, MD, Farhad Ravandi, MD, John M. Pagel, MD PhD, Jae H. Park, MD, B. Douglas Smith, MD, Moshe Yair Levy, MD, Elihu H. Estey, MD, Alexander E. Perl, MD, Hagop Kantarjian, MD, Dennis Earle, Dragan Cicic, MD, David A. Scheinberg, MD PhD

Blood (2015) 126 (23): 3794.

https://doi.org/10.1182/blood.V126.23.3794.3794

Published: 2015

Journal Articles

Engineered T Cell Receptor-Mimic Antibody, (TCRm) Chimeric Antigen Receptor (CAR) T Cells Against the Intracellular Protein Wilms Tumor-1 (WT1) for Treatment of Hematologic and Solid Cancers

Sarwish Rafiq, PhD, Tao Dao, MDPhD, Cheng Liu, PhD, David A. Scheinberg, MD PhD, Renier J Brentjens, MD PhD

Blood (2014) 124 (21): 2155.

https://doi.org/10.1182/blood.V124.21.2155.2155

Published: 2014

Journal Articles

Phase I Trial of Targeted Alpha-Particle Therapy Using Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33) in Combination with Low-Dose Cytarabine (LDAC) for Older Patients with Untreated Acute Myeloid Leukemia (AML)

Joseph G Jurcic, MD, Farhad Ravandi, MD, John M. Pagel, MD PhD, Jae H Park, MD, B. Douglas Smith, MD, Dan Douer, MD, Elihu H. Estey, MD, Hagop M. Kantarjian, MD, Richard L. Wahl, MD, Dennis Earle, Dragan Cicic, MD, David A. Scheinberg, MD PhD

Blood (2014) 124 (21): 5293.

https://doi.org/10.1182/blood.V124.21.5293.5293

Published: 2014

Journal Articles

A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL + leukemias

Leonid Dubrovsky, Dmitry Pankov, Elliott Joseph Brea, Tao Dao, Andrew Scott, Su Yan, Richard J O’Reilly, Cheng Liu, David A. Scheinberg

Blood (2014) 123 (21): 3296–3304.

https://doi.org/10.1182/blood-2014-01-549022

Published: 2014

Includes: Supplemental data

Journal Articles

A Bi-Specific T Cell Engaging Monoclonal Antibody (mAb) Derived From a TCR-Like Mab Specific For WT1/HLA-A0201 (ESK-BiTE) Shows a Potent Activity Against Human AML and Ph+ ALL In Mouse Models

Dmitry Pankov, MD, Tao Dao, MD, PhD, Yiyang Wang, Andrew Scott, Tatyana Korontsvit, MD, Victoria Zakhaleva, Nicholas Veomett, Michael Curcio, Ekaterina Doubrovina, MD, PhD, Richard J. O'Reilly, MD, Cheng Liu, PhD, David A. Scheinberg, MD, PhD

Blood (2013) 122 (21): 2521.

https://doi.org/10.1182/blood.V122.21.2521.2521

Published: 2013

NARROW

A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML

Potent and Target Specific Cytotoxicity of PRAME TCR Mimic CAR T Cells in KMT2A-Rearranged AML Patient-Derived Xenograft Model

Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blocker

A TCR mimic CAR T cell specific for NDC80 is broadly reactive with solid tumors and hematologic malignancies

Targeting PRAME with TCR-Mimic CAR T Cells in AML

A TCR Mimic Antibody-Directed CAR T Cell Specific for Intracellular NDC80 Is Broadly Cancer Reactive and Displays High Activity Against Hematological Malignancies

The Tumor Associated Antigen PRAME Exhibits Dualistic Functions That Are Targetable in Diffuse Large B-Cell Lymphoma

Epigenetic Drug Treatment Induces Presentation of New Class of Non-Exonic, Cryptic Neoantigens in Acute Myeloid Leukemia Cells

A Phase 2 Study of Actinium-225 ( 225 Ac)-Lintuzumab in Older Patients with Previously Untreated Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy

Identification of Cross-Reactive Targets of TCR-Based Therapeutic Agents within the Human Proteome

Immune reconstitution and remission in CML

Dual Inhibition of Histone Deacetylases and Phosphoinositide 3-Kinase Enhances Therapeutic Activity Against B Cell Lymphoma

CD47 Blockade Enhances Therapeutic Activity of TCR Mimic Antibodies to Ultra-Low Density Cancer Epitopes through Cytokine Feed Forward Mechanisms

Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 ( 225 Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML)

A Therapeutic TCR Mimic Monoclonal Antibody for Intracellular PRAME Protein in Leukemias

Phase I Trial of Targeted Alpha-Particle Immunotherapy with Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33) and Low-Dose Cytarabine (LDAC) in Older Patients with Untreated Acute Myeloid Leukemia (AML)

Engineered T Cell Receptor-Mimic Antibody, (TCRm) Chimeric Antigen Receptor (CAR) T Cells Against the Intracellular Protein Wilms Tumor-1 (WT1) for Treatment of Hematologic and Solid Cancers

Phase I Trial of Targeted Alpha-Particle Therapy Using Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33) in Combination with Low-Dose Cytarabine (LDAC) for Older Patients with Untreated Acute Myeloid Leukemia (AML)

A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL + leukemias

A Bi-Specific T Cell Engaging Monoclonal Antibody (mAb) Derived From a TCR-Like Mab Specific For WT1/HLA-A0201 (ESK-BiTE) Shows a Potent Activity Against Human AML and Ph+ ALL In Mouse Models

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only